Rodríguez BS, Almeida GJ, Carlos PJ

Language: Spanish
References: 26
Page: 346-352
PDF size: 482.77 Kb.

ABSTRACT

Introduction: Coronary heart disease is the leading cause of morbidity and mortality in diabetic patients. Many studies have compared medical therapy plus percutaneous intervention with medical therapy plus surgery in diabetic patients with multivessel disease. Bypass surgery remains the treatment of choice.
Objective: To characterize diabetic patients with multivessel coronary disease treated by percutaneous coronary intervention.
Method: An observational, descriptive and cross-sectional study was conducted in 57 diabetic patients with multivessel coronary disease who were treated by percuta-neous coronary intervention at the laboratory of hemodynamics of the Hermanos Ameijeiras Hospital from January 2010 to July 2011.
Results: There was a predominance of male patients (66.66 %), and the group aged 50-64 years was the most affected one (36.85%). The most common cardiovascular risk factor was hypertension (54.38 %), followed by dyslipidemia (49.12 %). Dyslipidemia and smoking predominated in the most affected age group. The most common diagnosis was stable angina (45 patients, 78.95%). The type of stent that was most commonly used was the drug-eluting stent (54.39 %), and the artery that most commonly underwent revascularization was the left anterior descending artery (36 patients, 63.15 %).
Conclusions: An association was found between the patients without angiographic success and the presence of dyslipidemia and obesity, and between the patients without procedural success and smoking and obesity.

REFERENCES

1. Ministerio de Salud Pública. Anuario estadístico de salud 2012. Edición en formato electrónico. La Ha-bana: MINSAP; 2013. [Consultado 2013 Abr 22]. Disponible en: http://files.sld.cu/dne/files/2013/04/anuario_2012.pdf

2. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation. 2012; 125(1):e2-220. [Erratum, Circulation 2012;125(22): e1002].

3. Pandolfi A, Cetrullo D, Polishuck R, Alberta MM, Ca-lafiore A, Pellegrini G, et al. Plasminogen activator inhibitor type 1 is increased in the arterial wall of type II diabetic subjects. Arterioscler Thromb Vasc Biol. 2001;21(8):1378-82.

4. López-Jiménez F, Cortés-Bergoderi M. Obesidad y corazón. Rev Esp Cardiol. 2011;64(2):140-9.

5. Hlatky MA, Boothroyd DB, Bravata DM, Boersma E, Booth J, Brooks MM, et al. Coronary artery bypass surgery compared with percutaneous coronary in-terventions for multivessel disease: a collaborative analysis of individual patient data from ten ran-domised trials. Lancet. 2009;373(9670):1190-7.

6. Smith SC, Faxon D, Cascio W, Schaff H, Gardner T, Jacobs A, et al. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group VI: revascularization in diabetic patients. Circulation. 2002;105(18):e165-9.

7. Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124(23):2610-42. [Erratum, Circulation. 2011;124 (25):e9956].

8. Coronary artery surgery study (CASS): a random-ized trial of coronary artery bypass surgery. Survival data. Circulation. 1983;68(5):939-50.

9. Eleven-year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina. The Veterans Administration Corona-ry Artery Bypass Surgery Cooperative Study Group. N Engl J Med. 1984;311(21):1333-9.

10. 10.Varnauskas E. Twelve-year follow-up of survival in the randomized European Coronary Surgery Study. N Engl J Med. 1988;319(6):332-7.

11. 11.Hueb W, Soares PR, Gersh BJ, César LA, Luz PL, Puig LB, et al. The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. J Am Coll Cardiol. 2004;43(10):1743-51.

12. 12.Rodriguez A, Bernardi V, Navia J, Baldi J, Grinfeld L, Martinez J, et al. Argentine Randomized Study: Co-ronary Angioplasty with Stenting versus Coronary Bypass Surgery in patients with MultipleVessel Disease (ERACI II): 30-day and one-year follow-up results. ERACI II Investigators. J Am Coll Cardiol. 2001;37(1):51-8.

13. 13.Rodriguez AE, Baldi J, Fernández Pereira C, Navia J, Rodriguez Alemparte M, Delacasa A, et al; ERACI II Investigators. Five-year follow-up of the Argentine randomized trial of coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple vessel disease (ERACI II). J AmColl Cardiol. 2005;46(4):582-8.

14. 14.Ix JH, Mercado N, Shlipak MG, Lemos PA, Boersma E, Lindeboom W, et al. Association of chronic kid-ney disease with clinical outcomes after coronary revascularization: the Arterial Revascularization Therapies Study (ARTS ii). Am Heart J. 2005;149(3): 512-9.

15. 15.Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA. 2005;294(10): 1215-23.

16. 16.Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, et al. Comparison of an everolimuseluting stent and a paclitaxel-eluting stent in pa-tients with coronary artery disease: a randomized trial. JAMA. 2008;299(16):1903-13.

17. 17.Kapur A, Hall RJ, Malik IS, Qureshi AC, Butts J, de Belder M, et al. Randomized comparison of percu-taneous coronary intervention with coronary artery bypass grafting in diabetic patients: 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol. 2010;55(5):432-40.

18. 18.Groot MW, Head SJ, Bogers AJ, Kappetein AP. Coro-nary revascularization in diabetic patients: a focus on the 3-year SYNTAX trial outcomes. Herz. 2012; 37(3):281-6.

19. 19.Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012;367(25):2375-84.

20. 20.Wägner AM, Sánchez JL, Pérez A. Diabetes mellitus y lipemia posprandial. Endroc Nutr. 2000;47(10): 311-21.

21. 21.Woodman RJ, Chew GT, Walts GF. Mechanisms, sig-nificance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid regulating therapy. Drugs. 2005;65(1):31-74.

22. 22.Januszewski AS, Alderson NL, Metz TO, Thorpe SR, Baynes JW. Role of lipids in chemical modification of proteins and development of complications in diabetes. Biochem Soc Trans. 2003;31(Pt 6):1413-6.

23. 23.González-Maqueda I. De la disfunción endotelial a la formación de la placa de ateroma. En: Rio A, De Pablo C, coordinadors. Manual de Medicina Pre-ventiva Publicación Oficial de la Sociedad Española de Cardiología. Sección de Cardiopatía Preventiva y Rehabilitación. Madrid: Scientific Communication Management; 2009. p. 25-41.

24. 24.González-Maqueda I. La enfermedad coronaria del diabético. Diagnóstico, pronóstico y tratamiento. Rev Esp Cardiol. 2007;7(Supl. H):29-41.

25. 25.Regar E, Serruys PW, Bode C, Holubarsch C, Guer-monprez JL, Wijns W, et al. Angiographic findings of the multicenter Randomized Study With the Siro-limus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation. 2002; 106(15):1949-56.

26. 26.Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, et al. Analysis of 14 trials comparing si-rolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356(10):1030-9.